These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 30526229)

  • 21. Expanded Gene Panel Use for Women With Breast Cancer: Identification and Intervention Beyond Breast Cancer Risk.
    O'Leary E; Iacoboni D; Holle J; Michalski ST; Esplin ED; Yang S; Ouyang K
    Ann Surg Oncol; 2017 Oct; 24(10):3060-3066. PubMed ID: 28766213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients.
    LaDuca H; Polley EC; Yussuf A; Hoang L; Gutierrez S; Hart SN; Yadav S; Hu C; Na J; Goldgar DE; Fulk K; Smith LP; Horton C; Profato J; Pesaran T; Gau CL; Pronold M; Davis BT; Chao EC; Couch FJ; Dolinsky JS
    Genet Med; 2020 Feb; 22(2):407-415. PubMed ID: 31406321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
    Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
    JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.
    Whitworth PW; Beitsch PD; Patel R; Rosen B; Compagnoni G; Baron PL; Simmons R; Brown EA; Gold L; Holmes D; Smith LA; Kinney M; Grady I; Clark P; Barbosa K; Lyons S; Riley L; Coomer C; Curcio L; Ruiz A; Khan S; MacDonald H; Hughes K; Hardwick MK; Heald B; Munro SB; Nielsen SM; Esplin ED
    JAMA Netw Open; 2022 Sep; 5(9):e2232787. PubMed ID: 36136330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals.
    Febbraro T; Robison K; Wilbur JS; Laprise J; Bregar A; Lopes V; Legare R; Stuckey A
    Gynecol Oncol; 2015 Jul; 138(1):109-14. PubMed ID: 25933682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence Patterns to National Comprehensive Cancer Network Guidelines for Referral of Women With Breast Cancer to Genetics Professionals.
    Stuckey A; Febbraro T; Laprise J; Wilbur JS; Lopes V; Robison K
    Am J Clin Oncol; 2016 Aug; 39(4):363-7. PubMed ID: 24710121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy.
    Dudley B; Karloski E; Monzon FA; Singhi AD; Lincoln SE; Bahary N; Brand RE
    Cancer; 2018 Apr; 124(8):1691-1700. PubMed ID: 29360161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
    J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants.
    Bernstein-Molho R; Friedman E; Kedar I; Laitman Y; Allweis TM; Gal-Yam EN; Feldman HB; Grinshpun A; Halpern N; Hartmajer S; Kadouri L; Katz LH; Kaufman B; Laish I; Levanon K; Philipsborn SL; Ludman M; Moran G; Peretz T; Reinstein E; Levi GR; Safra T; Shkedi S; Vinkler C; Levy Z; Goldberg Y
    Breast Cancer Res Treat; 2020 Jun; 181(2):445-453. PubMed ID: 32303989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative.
    Wood ME; Kadlubek P; Pham TH; Wollins DS; Lu KH; Weitzel JN; Neuss MN; Hughes KS
    J Clin Oncol; 2014 Mar; 32(8):824-9. PubMed ID: 24493722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
    Kurian AW; Ward KC; Hamilton AS; Deapen DM; Abrahamse P; Bondarenko I; Li Y; Hawley ST; Morrow M; Jagsi R; Katz SJ
    JAMA Oncol; 2018 Aug; 4(8):1066-1072. PubMed ID: 29801090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
    Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
    Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
    Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
    Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1.
    van der Post RS; Vogelaar IP; Manders P; van der Kolk LE; Cats A; van Hest LP; Sijmons R; Aalfs CM; Ausems MG; Gómez García EB; Wagner A; Hes FJ; Arts N; Mensenkamp AR; van Krieken JH; Hoogerbrugge N; Ligtenberg MJ
    Gastroenterology; 2015 Oct; 149(4):897-906.e19. PubMed ID: 26072394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Underdiagnosis of Hereditary Colorectal Cancers Among Medicare Patients: Genetic Testing Criteria for Lynch Syndrome Miss the Mark.
    Muller C; Nielsen SM; Hatchell KE; Yang S; Michalski ST; Hamlington B; Nussbaum RL; Esplin ED; Kupfer SS
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34585040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
    Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
    Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "Decoding hereditary breast cancer" benefits and questions from multigene panel testing.
    Colas C; Golmard L; de Pauw A; Caputo SM; Stoppa-Lyonnet D
    Breast; 2019 Jun; 45():29-35. PubMed ID: 30822622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
    Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
    Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.